$43,88
▼ $-0,16
(-0,36%)
Vol. 1.7M
12
Punteggio di Qualità
ok
Analisi approfondita
2/5
ok
Ricavi ✓
Utile netto ✓
>IPO ✗
Cap. mercato
$11.8B
P/E
17,3
ROE
31,6%
Margine
29,6%
D/E
0,00
Beta
0,42
52W
$32–$50
Consenso Wall Street
27 analisti · Apr 20266
Acquisto forte
9
Compra
11
Mantieni
1
Vendi
0
Vendita forte
55,6%
Rating Compra
Grafico dei Prezzi
Titoli simili
SMMT
Summit Therapeutics Inc
$13.0B
BBIO
BridgeBio Pharma Inc
$14.7B
NBIX
Neurocrine Biosciences Inc
P/E 33,0
$14.1B
MDGL
Madrigal Pharmaceuticals Inc
$13.2B
IONS
Ionis Pharmaceuticals Inc
$12.8B
BMRN
BioMarin Pharmaceutical Inc
P/E 21,9
$11.4B
PRAX
Praxis Precision Medicines Inc
$7.4B
ARWR
Arrowhead Pharmaceuticals Inc
$9.0B
PCVX
Vaxcyte Inc
$6.0B
Utili
Tasso di battuta: 100,0%
Prossimo report
Mag 11, 2026
Stima EPS: $0,73
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $0,73 | — | — |
| Dic 2025 | $0,82 | $0,88 | +$0,06 |
| Set 2025 | $0,63 | $0,69 | +$0,06 |
| Giu 2025 | $0,57 | $0,65 | +$0,08 |
Trend fondamentali
| Metrica | 2025-07-04 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 27.7% | 27.7% | 27.7% | 27.7% | 31.6% | 31.6% |
| P/E (TTM) | 20.90 | 16.96 | 18.37 | 17.28 | 17.36 | 17.33 |
| Net Margin | 32.5% | 27.0% | 27.0% | 27.0% | 29.6% | 29.6% |
| Gross Margin | 96.6% | 96.6% | 96.6% | 96.6% | 96.6% | 96.6% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.51 | 3.51 | 3.51 | 3.51 | 3.75 | 3.75 |
Rapporti chiave
ROA (TTM)
24,0%
P/S (TTM)
5,14
P/B
4,3
EPS (TTM)
$2,38
CF/Share
$0,36
Crescita ricavi 3A
+10,4%
52W High
$49,62
52W Low
$31,90
$31,90
Intervallo 52 settimane
$49,62
Як EXEL виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка EXEL vs аналоги Biotechnology
P/E
17,3
▼
8%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
5,1
▼
60%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
4,3
▲
76%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість EXEL vs аналоги Biotechnology
ROE
31,6%
▲
147%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Top livello
Net margin
29,6%
▲
110%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
96,6%
▲
23%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
24,0%
▲
151%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя EXEL vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
3,8
▼
16%
sotto
peer
(4,4)
vs Peer
vs Settore
Sotto media
Beta
0,4
▼
57%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів EXEL
EXEL
Mediana peer
Industria
EXEL прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
EXEL vs аналоги: ключові метрики
Ultima opinione AI
Grok
BUY
The price action shows a recent dip to a low of $39.71 on 2026-03-02 followed by a recovery to $41.41 close on 2026-03-23, positioning the current $41.37 as a solid entry point near support levels after volatility, with prior swings …
Mar 24, 2026